CHEK2: CanVIG-UK Gene-Specific Guidance
CanVIG-UK review of CHEK2 07/10/2025: Consensus to use relevant recommendations from the ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for ATM Version 1.4.0 (available at: https://clinicalgenome.org/affiliation/50039/).Additional points of specification are given below where applicable.Additional Note: For diagnostic analysis and reporting for cancer indications, the scope of this test indication currently includes canonical protein truncating variants and CHEK2 c.349A>G p.(Arg117Gly).
Institutions
- Cardiff and Vale University Health Board (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Nottingham University Hospitals NHS Trust (GB)
- Institute of Cancer Research (GB)
- University of Exeter (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Royal Devon & Exeter NHS Foundation Trust (GB)
- Western General Hospital (GB)
- NHS Greater Glasgow and Clyde (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- University of Manchester (GB)
- Children's Health Ireland at Crumlin (IE)
- Sheffield Children's NHS Foundation Trust (GB)
- Genomics England (GB)
- Birmingham Women’s and Children’s NHS Foundation Trust (GB)
- Queen Elizabeth University Hospital (GB)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2025-10-07
- DOI
- https://doi.org/10.5281/zenodo.15021529
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00